Q1 2025 saw sharply lower sales and a widened loss, driven by inventory write-downs and currency effects, while restructuring and new licensing deals position Enorama Pharma for a US-focused, white snus strategy. Additional funding is needed to complete the PMTA process.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.